EMA Authorised: Usgena (ustekinumab) — Stada Arzneimittel AG

View source ↗

Summary

Stada Arzneimittel AG authorized to market Usgena (ustekinumab) for Crohn's disease, psoriasis, psoriatic arthritis, and ulcerative colitis in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Psoriasis
• Psoriatic Arthritis
• Ulcerative Colitis

Drugs mentioned

• Usgena (ustekinumab)

Snippet

Status: Authorised. Therapeutic area: Crohn Disease;Psoriasis;Arthritis, Psoriatic;Colitis, Ulcerative. MAH: Stada Arzneimittel AG. Decision date: 10/08/2026